Leukemia Clinical Trials

Showing 3601-3620 of 10,987 trials

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

NCT06634667

This study aimed to evaluate the efficacy and safety of third-generation EGFR-TKI plus anlotinib as maintenance after chemotherapy plus immunotherapy in advanced NSCLC with small cell transformation after EGFR-TKI resistance.

Non-small Cell Lung Cancer

Hunan Province Tumor Hospital30 participantsStarted Nov 2024

Changsha, Hunan, China

RECRUITINGPhase 2

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

NCT06636552

The primary objective of this study is to evaluate the efficacy of the alternating D-PAD/D-CVD induction regimen followed by D-CVD consolidation regimen and maintenance with daratumumab monotherapy, in terms of PFS, in the first-line setting of pPCL.

Primary Plasma Cell Leukemia

Hellenic Society of Hematology43 participantsStarted Nov 2021

Athens, Attica, Greece • Athens, Attica, Greece • Athens, Attica, Greece +4 more locations

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

Related Searches

Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis

DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

The Pediatric Spine Foundation

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

Secondary Sclerosis Cholangitis Prospective

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Association of Urinary Incontinence With Depression, Insomnia, Frailty and Falls in Older Adults

Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations